

ESOPHAGOGASTRIC DISEASE ORIENTED GROUP

AGENDA

OPEN SESSION

VENUE: ROSSETTI ROOM, CHELSEA HOTEL, TORONTO

DATE SATURDAY, APRIL 29th, 2017

TIME: 08:00 – 09:00

CHAIR: DR. REBECCA WONG

-
- 08:00 WELCOME AND INTRODUCTION **DR. R. WONG**
- 08:00 ACTIVE/RECENTLY CLOSED TRIALS FOR UPDATE
- GA.1 (TOP GEAR):** A RANDOMIZED PHASE III TRIAL OF PREOPERATIVE CHEMORADIOTHERAPY VERSUS PREOPERATIVE CHEMOTHERAPY FOR RESECTABLE GASTRIC CANCER **DR. R. WONG**
- GA.1 (TOPGEAR):** OPTIMIZING ACCRUAL – LESSONS LEARNED FROM CANADA’S TOP ACCRUING SITE **DR. M. TEHFE (DR. M. LIBERMAN)**
- GA.3 (INTEGRATE II) -** A RANDOMIZED PHASE 3 DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF REGORAFENIB IN REFRACTORY ADVANCED OESOPHAGO-GASTRIC CANCER (AOGC) **DR. T. ALCINDOR**
- IND 214:** A PHASE I/II STUDY OF MG1 MARABA/MAGE-A3 (MG1MA3), WITH AND WITHOUT ADENOVIRUS VACCINE, WITH TRANSGENIC MAGE-A3 INSERTION (ADMA3) IN PATIENTS WITH INCURABLE ADVANCED/METASTATIC MAGE-A3-EXPRESSING SOLID TUMOURS **DR. D. JONKER**
- 08:30 NEW CONCEPTS IN DEVELOPMENT
- A RANDOMIZED PHASE II STUDY OF CISPLATIN + GEMCITABINE VS STANDARD OF CARE IN PATIENTS WITH EBV+ GASTRIC CANCER. **DR. R. WONG (DR. ERIC CHEN)**
- THE NEEDS TRIAL:** NEOADJUVANT CHEMORADIOTHERAPY FOR ESOPHAGEAL SQUAMOUS CELL CARCINOMA VERSUS DEFINITIVE CHEMORADIOTHERAPY WITH SALVAGE SURGERY AS NEEDED **DR. R. WONG**
- PHASE II/ III TRIAL COMPARING TWO CHEMOTHERAPY REGIMENS IN DEFINITIVE CHEMORADIOTHERAPY FOLLOWED BY PET/ BIOPSY DIRECTED BRACHYTHERAPY FOR PATIENTS WITH CANCER OF ESOPHAGUS WHO ARE NOT ELIGIBLE FOR SURGERY
- **DR. A. MAHMUD**
- 08:55 INTERGROUP TASK FORCE UPDATE **DR. R. WONG**
- 09:00 CLOSING REMARKS